This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
Patients with HR+/HER2− metastatic breast cancer without previous systemic therapy were randomly assigned to receive either metronomic capecitabine plus AI or AI alone.
Medscape Medical News